Program
Crizotinib
Also written as “crizotinib”, “PF-02341066” and “Crizotinib plus sunitinib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uveal Melanoma · Neoplasms · Lymphoma · Lymphoma, Large-Cell, Anaplastic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 291 open or running | phase 4since Jul 19, 2018 | Dec 29, 2007 | Mar 21, 2028phase 4 · NCT05160922 |
| Hoffmann-La Roche | 10 open or running | phase 3since Jun 20, 2017 | Jun 20, 2017 | none ahead |
| IDEAYA Biosciences | 11 open or running | phase 3since Aug 21, 2026 | Aug 21, 2026 | Mar 2034phase 3 · NCT07804186 |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Dec 29, 2007.
- Dec 22, 2011Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT01500824
- Feb 25, 2012Phase 1 study in HealthyPfizer · NCT01549574 · 16 enrolled · Belgium
- Mar 30, 2012Phase 1 study in Advanced CancerPfizer · NCT01576406 · 88 enrolled · United States
- Jul 10, 2012Phase 3 study in Carcinoma, Non-Small-Cell LungPfizer · NCT01639001 · 207 enrolled · China, Hong Kong, Malaysia and more
- Sep 5, 2013Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT01945021 · 129 enrolled · China, Japan, Korea, Republic of and more
- Nov 26, 2013Phase 1 study in CarcinomaPfizer · NCT01999972 · 50 enrolled · United States, United Kingdom
- Dec 5, 2013Phase 1 study in HealthyPfizer · NCT02006277 · 21 enrolled · Belgium
- Jul 22, 2015Phase 1 study in Lung NeoplasmsPfizer · NCT02511184 · 9 enrolled · United States
- Apr 26, 2017Phase 1 study in HealthyPfizer · NCT03137134 · 18 enrolled · United States
- Jun 20, 2017Hoffmann-La Roche's first study: phase 3 study in NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT03194893 · 50 enrolled · United States, France, Hong Kong and more
- Jul 19, 2018Phase 4 study in ALK or ROS1-positive NSCLCPfizer · NCT03672643 · 41 enrolled · China
- Apr 20, 2021Phase 1 study in Healthy ParticipantsPfizer · NCT04856293 · 25 enrolled · United States
- Dec 6, 2021Phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05160922 · 27 enrolled · China, Italy, Japan and more
- Aug 21, 2026IDEAYA Biosciences's first study: phase 3 study in Uveal MelanomaNew to IDEAYA BiosciencesIDEAYA Biosciences · NCT07804186 · 450 planned · United States, Australia, Canada and more
Ahead
- Mar 21, 2028Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05160922
- Mar 2034Primary completion: phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT07804186
TargetBeta
“An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity”NCIt, by rule
“Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor”ChEMBL 37, by rule
Studies
All 31 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07804186Uveal Melanoma · United States, Australia, Canada and more | 3 | Recruiting | IDEAYA Biosciences | Mar 2034 | 450 |
| NCT05160922Carcinoma, Non-Small-Cell Lung · China, Italy, Japan and more | 4 | Active, not recruiting | Pfizer | Mar 21, 2028 | 27 |
| NCT04856293Healthy Participants · United States | 1 | Completed | Pfizer | Dec 15, 2021 | 25 |
| NCT03672643ALK or ROS1-positive NSCLC · China | 4 | Terminated | Pfizer | Sep 28, 2023 | 41 |
| NCT03194893Neoplasms · United States, France, Hong Kong and more | 3 | Completed | Hoffmann-La Roche | Sep 18, 2025 | 50 |
| NCT03137134Healthy · United States | 1 | Completed | Pfizer | Sep 19, 2017 | 18 |
| NCT02511184Lung Neoplasms · United States | 1 | Terminated | Pfizer | Dec 2017 | 9 |
| NCT02006277Healthy · Belgium | 1 | Completed | Pfizer | Mar 2014 | 21 |
| NCT01999972Carcinoma · United States, United Kingdom | 1 | Completed | Pfizer | Feb 22, 2017 | 50 |
| NCT01945021Carcinoma, Non-Small-Cell Lung · China, Japan, Korea, Republic of and more | 2 | Completed | Pfizer | Jul 31, 2015 | 129 |
| NCT01639001Carcinoma, Non-Small-Cell Lung · China, Hong Kong, Malaysia and more | 3 | Completed | Pfizer | Jun 30, 2015 | 207 |
| NCT01576406Advanced Cancer · United States | 1 | Completed | Pfizer | Jun 2016 | 88 |
| NCT01549574Healthy · Belgium | 1 | Completed | Pfizer | May 2012 | 16 |
| NCT01500824Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Pfizer | May 2016 | 0 |
| NCT01441388Carcinoma, Renal Cell | 1 | Withdrawn | Pfizer | Nov 2013 | 0 |
| NCT01419041Renal Insufficiency · United States | 1 | Completed | Pfizer | Aug 2012 | 16 |
| NCT01297595Healthy · Belgium | 1 | Completed | Pfizer | Apr 2011 | 22 |
| NCT01250730Healthy · Japan | 1 | Completed | Pfizer | Jan 2011 | 18 |
| NCT01168934Healthy · Belgium | 1 | Completed | Pfizer | Sep 2010 | 14 |
| NCT01154218Healthy · Belgium | 1 | Completed | Pfizer | Nov 2010 | 36 |
| NCT01149785Healthy · United States | 1 | Completed | Pfizer | Sep 2010 | 15 |
| NCT01147055Healthy · United States | 1 | Completed | Pfizer | Oct 2010 | 15 |
| NCT01125904Healthy · United States | 1 | Completed | Pfizer | Jun 2010 | 5 |
| NCT01121588Neoplasms · United States, China, Italy and more | 1 | Terminated | Pfizer | Sep 7, 2023 | 44 |
| NCT01121575Carcinoma, Non-Small-Cell Lung · United States, Australia | 1 | Completed | Pfizer | Feb 2014 | 70 |
| NCT01082380Healthy Volunteer · United States | 1 | Completed | Pfizer | Apr 2010 | 6 |
| NCT00965731Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Pfizer | Dec 2011 | 27 |
| NCT00939731Healthy · United States | 1 | Completed | Pfizer | Aug 2009 | 24 |
| NCT00932893Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Completed | Pfizer | Mar 2012 | 347 |
| NCT00932451Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 2 | Completed | Pfizer | Mar 2015 | 1,069 |
| NCT00585195Lymphoma, Large-Cell, Anaplastic · United States, Australia, Japan and more | 1 | Completed | Pfizer | Jul 30, 2020 | 596 |
How it is read
Names in the registry
- “crizotinib”, 21 entries
- “PF-02341066”, 12 entries
- “Crizotinib”, 11 entries
- “Crizotinib plus sunitinib”, 2 entries
- “Crizotinib (Xalkori)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Uveal Melanoma, 1 study
- Neoplasms, 1 study
- Lymphoma, 1 study
- Lymphoma, Large-Cell, Anaplastic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.